Omvoh
What Omvoh is used for
Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Omvoh
- Active substance
- mirikizumab
- Disease area
- Colitis, Ulcerative
- Medicine group
- Immunosuppressants
- ATC code
- L04AC
- Marketing authorisation holder
- Eli Lilly Nederland B.V.
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Omvoh
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Omvoh used for?
Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
What is the active substance in Omvoh?
Omvoh contains mirikizumab.
Who makes Omvoh?
The EU marketing authorisation holder is Eli Lilly Nederland B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU